Health Care & Life Sciences » Biotechnology | Marina Biotech Inc.

Marina Biotech Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
909.00
1,824.00
261.80
105.30
106.40
1,522
Total Accounts Receivable
5.00
500.00
-
-
-
31
Other Current Assets
128.00
192.00
-
211.10
18.60
10
Total Current Assets
1,042.00
2,516.00
261.80
316.50
124.90
1,563
Intangible Assets
6,700.00
6,700.00
-
5,870.00
6,058.80
-
Total Assets
7,742.00
9,216.00
261.80
6,186.40
6,183.70
1,962
ST Debt & Current Portion LT Debt
1,623.00
-
-
686.00
1,906.30
Accounts Payable
1,614.00
687.00
11.00
663.30
1,033.40
Other Current Liabilities
2,979.00
1,255.00
124.20
1,618.40
2,795.90
Total Current Liabilities
6,216.00
1,942.00
135.20
2,967.70
5,735.50
Deferred Taxes
2,345.00
2,345.00
-
-
-
Other Liabilities
6,245.00
9,300.00
36.50
-
-
Total Liabilities
14,806.00
13,587.00
171.70
2,967.70
5,735.50
Common Equity (Total)
7,064.00
4,371.00
90.20
3,218.80
448.20
Total Shareholders' Equity
7,064.00
4,371.00
90.20
3,218.80
448.20
Total Equity
7,064.00
4,371.00
90.20
3,218.80
448.20
Liabilities & Shareholders' Equity
7,742.00
9,216.00
261.80
6,186.40
6,183.70

About Marina Biotech

View Profile
Address
200 Technology Square
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.modernatx.com
Updated 07/08/2019
Marina Biotech, Inc. is a biotechnology company, which is engages in the discovery, development, and commercialization of drug therapeutics for hypertension. It offers Perstalia, which contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension. The company was founded on September 23, 1983 and is headquartered in City of Industry, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.